Clinical Trials Browser

Phase 2 × ER+ and AR+ Breast Cancer × Clear all

NCT02746328 2024-02-26

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

Phase 2 Withdrawn

ER+ and AR+ Breast Cancer

NCT02463032 2020-12-09

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

Phase 2 Completed

136 enrolled 14 charts

ER+ and AR+ Breast Cancer